相似文献
1
Antimicrobial susceptibilities of Bordetella species isolated in a Multicenter Pertussis Surveillance Project.
Antimicrob Agents Chemother. 1988 Jan;32(1):137-40. doi: 10.1128/AAC.32.1.137.
2
Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015.
Cent Eur J Public Health. 2017 Dec;25(4):282-286. doi: 10.21101/cejph.a4948.
3
Susceptibility of Bordetella pertussis to five quinolone antimicrobic drugs.
Diagn Microbiol Infect Dis. 1987 Oct;8(2):131-3. doi: 10.1016/0732-8893(87)90162-3.
4
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine).
Antimicrob Agents Chemother. 1998 Apr;42(4):965-6. doi: 10.1128/AAC.42.4.965.
5
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to seven fluoroquinolones.
Antimicrob Agents Chemother. 1990 Nov;34(11):2287-8. doi: 10.1128/AAC.34.11.2287.
6
[Susceptibility testing and molecular epidemiology of clinical strains of Bordetella pertussis isolated in Japan from 2001 to 2002].
Kansenshogaku Zasshi. 2004 May;78(5):420-7. doi: 10.11150/kansenshogakuzasshi1970.78.420.
7
Antimicrobial susceptibility of Bordetella pertussis strains isolated from 1960 to 1981.
Antimicrob Agents Chemother. 1982 Apr;21(4):666-7. doi: 10.1128/AAC.21.4.666.
8
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem.
Antimicrob Agents Chemother. 1996 Mar;40(3):807-8. doi: 10.1128/AAC.40.3.807.
9
Antibiotic resistance of degraded strains of Bordetella pertussis.
Antimicrob Agents Chemother. 1984 Apr;25(4):537-8. doi: 10.1128/AAC.25.4.537.
10
The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis.
J Antimicrob Chemother. 1998 Mar;41 Suppl B:23-7. doi: 10.1093/jac/41.suppl_2.23.
引用本文的文献
1
Macrolide Resistance in : Current Situation and Future Challenges.
Antibiotics (Basel). 2022 Nov 7;11(11):1570. doi: 10.3390/antibiotics11111570.
2
Genomic and transcriptomic variation in Bordetella spp. following induction of erythromycin resistance.
J Antimicrob Chemother. 2022 Oct 28;77(11):3016-3025. doi: 10.1093/jac/dkac272.
3
Occupational Health Update: Focus on Preventing the Acquisition of Infections with Pre-exposure Prophylaxis and Postexposure Prophylaxis.
Infect Dis Clin North Am. 2016 Sep;30(3):729-57. doi: 10.1016/j.idc.2016.04.008.
4
Isolation of Bordetella bronchiseptica from blood and a pancreatic abscess.
J Clin Microbiol. 2015 May;53(5):1778-80. doi: 10.1128/JCM.00175-15. Epub 2015 Mar 4.
5
A simplified method for testing Bordetella pertussis for resistance to erythromycin and other antimicrobial agents.
J Clin Microbiol. 2000 Mar;38(3):1151-5. doi: 10.1128/JCM.38.3.1151-1155.2000.
6
State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis.
Infection. 1998 Jul-Aug;26(4):242-6. doi: 10.1007/BF02962373.
7
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.
Antimicrob Agents Chemother. 1998 Jul;42(7):1868. doi: 10.1128/AAC.42.7.1868.
8
Bordetella parapertussis infection in children: epidemiology, clinical symptoms, and molecular characteristics of isolates.
J Clin Microbiol. 1998 Apr;36(4):999-1002. doi: 10.1128/JCM.36.4.999-1002.1998.
9
Update of epidemiology, diagnosis, and treatment of pertussis.
Eur J Clin Microbiol Infect Dis. 1996 Mar;15(3):189-93. doi: 10.1007/BF01591352.
10
Comparison of media for agar dilution susceptibility testing of Bordetella pertussis and Bordetella parapertussis.
Eur J Clin Microbiol Infect Dis. 1995 Sep;14(9):775-9. doi: 10.1007/BF01690992.
本文引用的文献
1
Pharmacokinetics and tissue penetration of ciprofloxacin.
Antimicrob Agents Chemother. 1983 Nov;24(5):784-6. doi: 10.1128/AAC.24.5.784.
2
In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria.
Antimicrob Agents Chemother. 1984 Jul;26(1):97-100. doi: 10.1128/AAC.26.1.97.
3
Antibiotic resistance of degraded strains of Bordetella pertussis.
Antimicrob Agents Chemother. 1984 Apr;25(4):537-8. doi: 10.1128/AAC.25.4.537.
4
In-vitro sensitivity of Bordetella pertussis.
J Antimicrob Chemother. 1983 May;11(5):407-11. doi: 10.1093/jac/11.5.407.
5
Antimicrobial susceptibility of Bordetella pertussis strains isolated from 1960 to 1981.
Antimicrob Agents Chemother. 1982 Apr;21(4):666-7. doi: 10.1128/AAC.21.4.666.
6
Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography.
Antimicrob Agents Chemother. 1982 May;21(5):808-10. doi: 10.1128/AAC.21.5.808.
7
Susceptibility of Bordetella pertussis to cephalosporin derivatives and imipenem.
Antimicrob Agents Chemother. 1984 Oct;26(4):604-5. doi: 10.1128/AAC.26.4.604.
8
Demonstration of R factors in Bordetella bronchiseptica isolated from pigs.
Antimicrob Agents Chemother. 1973 May;3(5):555-8. doi: 10.1128/AAC.3.5.555.
9
Susceptibility of Bordetella pertussis to nine antimicrobial agents.
Am J Dis Child. 1969 Mar;117(3):276-80. doi: 10.1001/archpedi.1969.02100030278004.
10
Epidemics of parapertussis. 20 years' observations in Denmark.
Lancet. 1971 Jun 12;1(7711):1195-8. doi: 10.1016/s0140-6736(71)91713-2.
Zotero 插件